Revealing the therapeutic properties of gut microbiota: transforming cancer immunotherapy from basic to clinical approaches
Medical Oncology · 2024
DOI: 10.1007/s12032-024-02416-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medical Oncology, 2024. Verfasst von Rudradeep Hazra und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Technology, Kolkata-Group of Institutions, NSHM Knowledge Campus, 124, B. L. Saha Road, Tara Park, Behala, Kolkata, West…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Immunotherapy, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 189 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Technology, Kolkata-Group of Institutions, NSHM Knowledge Campus, 124, B. L. Saha Road, Tara Park, Behala, Kolkata, West Bengal, 700053, India.
- Department of Pharmaceutical Technology, Kolkata-Group of Institutions, NSHM Knowledge Campus, 124, B. L. Saha Road, Tara Park, Behala, Kolkata, West Bengal, 700053, India. souvikroy35@gmail.com.
Zitieren
APA
Hazra, R., Chattopadhyay, S., Mallick, A., Gayen, S., & Roy, S. (2024). Revealing the therapeutic properties of gut microbiota: transforming cancer immunotherapy from basic to clinical approaches. Medical Oncology. https://doi.org/10.1007/s12032-024-02416-3
Vancouver
Hazra R, Chattopadhyay S, Mallick A, Gayen S, Roy S. Revealing the therapeutic properties of gut microbiota: transforming cancer immunotherapy from basic to clinical approaches. Medical Oncology. 2024. doi:10.1007/s12032-024-02416-3
BibTeX
@article{Hazra2024,
author = {Hazra, Rudradeep and Chattopadhyay, Soumyadeep and Mallick, Arijit and Gayen, Sakuntala and Roy, Souvik},
title = {Revealing the therapeutic properties of gut microbiota: transforming cancer immunotherapy from basic to clinical approaches},
journal = {Medical Oncology},
year = {2024},
doi = {10.1007/s12032-024-02416-3}
}
EUVIMED